Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 754091 (ezabenlimab) in advanced solid tumors
NCT02952248Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2016
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of ezabenlimab in non-small cell lung cancer (NSCLC), bladder cancer, melanoma and 9 more (7 cohorts), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-Limiting Toxicities at 3 weeks and Objective Response up to 853 days. Started Nov 2016; status: completed.
02
Drugs
ezabenlimab
03
Conditions
non-small cell lung cancer (NSCLC)bladder cancermelanomagastric cancer (GC)ovarian cancer
Beyond the preview
Go deeper on NCT02952248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952248.